Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Mar;20(1):23-37.
doi: 10.1007/s40268-020-00293-5.

Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations

Sanela Tarabar  1   2 , Debra Kelsh  3 , Bradley Vince  3 , Rina Leyva  4 , Dongweon Song  5 , Kyle Matschke  5 , David E Kellstein  4 , Suzanne Meeves  4 , Mario Cruz-Rivera  4
Affiliations
Clinical Trial

Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations

Sanela Tarabar et al. Drugs R D. 2020 Mar.

Abstract

Introduction: A fixed-dose combination (FDC) of ibuprofen and acetaminophen has been developed that provides greater analgesic efficacy than either agent alone at the same doses without increasing the risk for adverse events.

Methods: We report three clinical phase I studies designed to assess the pharmacokinetics (PK) of the FDC of ibuprofen/acetaminophen 250/500 mg (administered as two tablets of ibuprofen 125 mg/acetaminophen 250 mg) in comparison with its individual components administered alone or together, and to determine the effect of food on the PK of the FDC. Two studies in healthy adults aged 18-55 years used a crossover design in which subjects received a single dose of each treatment with a 2-day washout period between each. In the third study, the bioavailability of ibuprofen and acetaminophen from a single oral dose of the FDC was assessed in healthy adolescents aged 12-17 years, inclusive.

Results: A total of 35 and 46 subjects were enrolled in the two adult studies, respectively, and 21 were enrolled in the adolescent study. Ibuprofen and acetaminophen in the FDC were bioequivalent to the monocomponents administered alone or together. With food, the maximum concentration (Cmax) for ibuprofen and acetaminophen from the FDC was reduced by 36% and 37%, respectively, and time to Cmax (i.e. tmax) was delayed. Overall drug exposure to ibuprofen or acetaminophen in the fed versus fasted states was similar. In adolescents, overall exposure to acetaminophen and ibuprofen was comparable with that in adults, with a slightly higher overall exposure to ibuprofen. Exposure to acetaminophen and ibuprofen in adolescents aged 12-14 years was slightly higher versus those aged 15-17 years. Adverse events were similar across all treatment groups.

Conclusions: The FDC of ibuprofen/acetaminophen 250/500 mg has a PK profile similar to its monocomponent constituents when administered separately or coadministered, indicating no drug-drug interactions and no formulation effects. Similar to previous findings for the individual components, the rates of absorption of ibuprofen and acetaminophen from the FDC were slightly delayed in the presence of food. Overall, adolescents had similar exposures to acetaminophen and ibuprofen as adults, while younger adolescents had slightly greater exposure than older adolescents, probably due to their smaller body size. The FDC was generally well tolerated.

PubMed Disclaimer

Conflict of interest statement

Sanela Tarabar, Rina Leyva, Dongweon Song, and Kyle Matschke are employees of and may own stock/stock options in Pfizer Inc. David E. Kellstein and Mario Cruz-Rivera were employees of Pfizer Inc. at the time this research was conducted and may own stock/stock options in Pfizer Inc. Suzanne Meeves was an employee of Pfizer Inc. at the time this research was conducted. Debra Kelsh and Bradley Vince declare they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Median plasma ibuprofen concentration over time following a single oral dose: a Study 1; b Study 2; c Study 3. Note that plasma concentrations for IBU 200 mg in Study 1 are dose-normalized. APAP acetaminophen, FDC fixed-dose combination, IBU ibuprofen
Fig. 2
Fig. 2
Median plasma acetaminophen concentration over time following a single oral dose: a Study 1; b Study 2; c Study 3. Note that plasma concentrations for APAP ER 650 mg in Study 1 are dose-normalized. APAP acetaminophen, ER extended-release, FDC fixed-dose combination, IBU ibuprofen
See this image and copyright information in PMC

References

    1. Dickman A. Choosing over-the-counter analgesics. Pharm J. 2008;281:631.
    1. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children’s pain or fever: a meta-analysis. Arch Pediatr Adolesc Med. 2004;158:521–526. doi: 10.1001/archpedi.158.6.521. - DOI - PubMed
    1. Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. Non-prescription (OTC) oral analgesics for acute pain—an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;(11):CD010794. - PMC - PubMed
    1. Goldman RD, Ko K, Linett LJ, Scolnik D. Antipyretic efficacy and safety of ibuprofen and acetaminophen in children. Ann Pharmacother. 2004;38:146–150. doi: 10.1345/aph.1C391. - DOI - PubMed
    1. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44:489–506. doi: 10.1345/aph.1M332. - DOI - PubMed